GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Gross Margin %

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Gross Margin % : 58.27% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Santen Pharmaceutical Co's Gross Profit for the three months ended in Dec. 2023 was $312 Mil. Santen Pharmaceutical Co's Revenue for the three months ended in Dec. 2023 was $535 Mil. Therefore, Santen Pharmaceutical Co's Gross Margin % for the quarter that ended in Dec. 2023 was 58.27%.


The historical rank and industry rank for Santen Pharmaceutical Co's Gross Margin % or its related term are showing as below:

SNPHY' s Gross Margin % Range Over the Past 10 Years
Min: 58.81   Med: 61.01   Max: 65.17
Current: 60.57


During the past 13 years, the highest Gross Margin % of Santen Pharmaceutical Co was 65.17%. The lowest was 58.81%. And the median was 61.01%.

SNPHY's Gross Margin % is ranked better than
73.33% of 990 companies
in the Drug Manufacturers industry
Industry Median: 46.8 vs SNPHY: 60.57

Santen Pharmaceutical Co had a gross margin of 58.27% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Santen Pharmaceutical Co was -0.80% per year.


Santen Pharmaceutical Co Gross Margin % Historical Data

The historical data trend for Santen Pharmaceutical Co's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Gross Margin % Chart

Santen Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.22 60.74 60.65 58.81 59.52

Santen Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.31 65.30 58.52 59.91 58.27

Competitive Comparison of Santen Pharmaceutical Co's Gross Margin %

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Gross Margin % falls into.



Santen Pharmaceutical Co Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Santen Pharmaceutical Co's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )=Gross Profit (A: Mar. 2023 ) / Revenue (A: Mar. 2023 )
=1242.6 / 2087.596
=(Revenue - Cost of Goods Sold) / Revenue
=(2087.596 - 845.028) / 2087.596
=59.52 %

Santen Pharmaceutical Co's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=311.7 / 534.978
=(Revenue - Cost of Goods Sold) / Revenue
=(534.978 - 223.264) / 534.978
=58.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Santen Pharmaceutical Co had a gross margin of 58.27% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Santen Pharmaceutical Co Gross Margin % Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020